Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Stewart

Orthopaedic Surgery Sarasota, FL Medical Doctor

NPI 1235380841 CMS profile 1138891

5831 Bee Ridge Rd Ste 300, Sarasota, FL 34233

Open in the dashboard

General payments

$6,432

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Stewart of Sarasota, FL is reported in the CMS Open Payments database as having received $6,432 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,322 10
2024 General $535 8
2023 General $812 9
2022 General $156 6
2021 General $708 14
2020 General $148 9
2019 General $750 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Stewart
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Charles Stewart were reported at $3,322. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Charles Stewart Orthopaedic Surgery median Middle half National median
2019 $750 $644 $140–$2,844 $163
2020 $148 $312 $75–$1,860 $114
2021 $708 $520 $117–$2,495 $132
2022 $156 $598 $128–$2,731 $149
2023 $812 $461 $128–$2,264 $160
2024 $535 $497 $134–$2,475 $164
2025 $3,322 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,083 24 payments
  2. MVP Orthopedics Inc $224 6 payments
  3. Flexion Therapeutics, Inc. $187 15 payments
  4. MicroPort Orthopedics Inc $129 3 payments
  5. Orthofix Medical, Inc. $115 3 payments
  6. Pacira Pharmaceuticals Incorporated $75 3 payments
  7. DePuy Synthes Sales Inc. $71 4 payments
  8. Medtronic USA, Inc. $65 3 payments
  9. Trice Medical, Inc. $56 1 payment
  10. Biocomposites Inc $53 1 payment
  11. Other $374 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,977 79 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,954 1 payment
  3. Education $501 2 payments
Products named General payments · program years 2019–2025
  1. MAKO $3,742 9 payments
  2. ACCOLADE Hips $358 3 payments
  3. ACTISHIELD $297 1 payment
  4. Zilretta $187 15 payments
  5. HOFFMANN $181 2 payments
  6. T2 $161 1 payment
  7. AXSOS $161 1 payment
  8. ACCOLADE Hips $139 1 payment
  9. MOTIONSENSE DIGITAL GONIOMETER $133 2 payments
  10. MPO Hip System $129 3 payments
  11. Other $1,225 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,948

Median for Orthopedic Surgery: 203

Drug cost

$15,366

Median for Orthopedic Surgery: $1,433

Branded share of claims

12%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 237 $4,318
Ondansetron Odt Ondansetron Brand 233 $2,041
Cephalexin Generic 235 $1,831
Oxycodone Hcl Generic 227 $1,789
Mupirocin Generic 264 $1,480
Pregabalin Generic 69 $1,296
Tramadol Hcl Generic 247 $820
Doxycycline Hyclate Generic 38 $499
Diclofenac Sodium Generic 28 $485
Diazepam Generic 128 $383

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$962,084

Of which drugs: $250,877

Medicare patients

1,838

Average age 76

Services billed

93,306

1,081 women, 757 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Ischemic heart disease 33%
Diabetes 20%
Depression 20%
Osteoporosis 19%
Atrial fibrillation 18%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 202 14,088 $190,523
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 45 3,136 $42,959
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 14 1,500 $8,204
Injection, methylprednisolone acetate, 1 mg J1010 Office 538 66,168 $6,736
Injection, methylprednisolone acetate, 80 mg J1040 Office 211 269 $1,959
Injection, ketorolac tromethamine, per 15 mg J1885 Office 32 158 $83

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $6
$6 — 3,136
Exparel
  • Pacira Pharmaceuticals Incorporated $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record